Top Markets
#1 0G 0G +34.27%
#2 Nockchain Nockchain +23.06%
#3 Axelar Axelar +21.57%
#4 Fake World Assets Fake World Assets +19.15%
#5 Full Moon Full Moon +17.70%
#6 Zora Zora +17.54%
#7 Merlin's Seal BTC Merlin's Seal BTC +16.09%
#8 Notcoin Notcoin +16.06%
#9 ADO Protocol ADO Protocol +15.57%
#10 StonkBroker StonkBroker +15.35%
Coin of the day
0G 0G
設定
言語
日本
通貨
USD
テーマ
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
株式のランク #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
株価
$8.46
最終同期: 2026-08-28
時価総額
$514.33M
変化（1日）
-2.08%
変化（1年）
128.03%
国
US
取引 Kyverna Therapeutics, Inc. (KYTX)

カテゴリー

Healthcare
Kyverna Therapeutics, Inc.（KYTX）の収益
Aug 2026 時点の収益 TTM: 0
Kyverna Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Kyverna Therapeutics, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH